. 2009 Jul 5;9:106. doi: 10.1186/1471-2334-9-106

Table 2.

Primary and Secondary Outcome Measures with Prophylaxis versus Placebo

Outcome Measure	RR all Antibody Prophyaxis	RR Palivizumab	RR RSV-IGIV
RSV Hospitalization	0.53 (0.43, 0.66), P < 0.00001	0.50 (0.38, 0.66); 3 ^14,15,16 studies, 1663 treated, P < 0.00001	0.59 (0.42, 0.83); 3 ^11,12,13 studies, 533 treated, P = 0.002

ICU Admission	0.39 (0.21, 0.70), P = 0.002	0.29 (0.14, 0.59); 2 ^15,16 studies, 1641 treated, P = 0.0007	0.50 (0.24, 1.04); 3^11,12,13studies, 533 treated, P = 0.06

Mechanical Ventilation	0.76 (0.43, 1.36), P = 0.36	1.10 (0.20, 6.09); 2^15,16studies, 1641 treated, P = 0.91	0.77 (0.33, 1.79); 3^11,12,13studies, 533 treated, P = 0.55

RSV Infection	0.78 (0.60, 1.01), P = 0.06	0.45 (0.09, 2.22); 1¹⁴study, 22 treated, P = 0.33	0.79 (0.61, 1.03); 2^11,13studies, 283 treated, P = 0.08

All Cause Mortality	0.95 (0.55, 1.65), P = 0.86	0.71 (0.42, 1.19); 2^15,16studies, 1641 treated, P = 0.19	1.53 (0.65, 3.61); 3^11,12,13studies, 533 treated, P = 0.33